HERIZON_GEA_01 Archives

First-line novel bispecific antibody improves progression-free survival in patients with previously untreated HER2-positive advanced gastric cancer

The HERIZON-GEA-01 open-label, phase 3 clinical trial was designed to compare first-line treatment with the bispecific antibody zanidatamab plus chemotherapy…